Grünenthal focusses on developing new therapies/medicines for patients. In order to make these therapies/medicines available to patients, Grünenthal is conducting rigorous clinical trials to assess the safety and efficacy of the investigational therapies/medicines, which if proven, will enable the necessary approvals from regulatory authorities. This process will allow patients to have broad access to these medicines. We encourage patients who want access to our investigational therapies/medicines to participate in our clinical trial programs. Given the investigational status of our compounds in clinical development, we currently do not grant expanded access.